Emergent BioSolutions Inc.

NYSE:EBS

Biotechnology

Healthcare
$5.50 -2.58%

-$0.21 today

Market cap
$282.78M
Beta
2.33
P/E (TTM)
-47.9
EPS (TTM)
-$0.17
52W Low $5.62High $14.06

Volume 0.82M

Average 0.78M

EBS Net Income

Bottom-line profit after all expenses, interest, and taxes.

Emergent BioSolutions Inc.NYSE: EBS

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income dips below year-ago levels

Q1 FY2026 net income of $6.8M fell 90.0% year over year, behind the +93.5% change in trailing-twelve-month net income.

Context

  • Net income amounted to 7.1% of revenue in FY2025, down 11.2 pp from a year earlier.
  • Net income increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 2 analysts of $15.59M (-70.4%) for the fiscal year ending Dec 2026, a slowdown from the +127.6% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$6.8M+112.5% QoQ
Last fiscal yearDec 2025
$52.6M+127.6% YoY
LTMMar 2026
-$8.6M+93.5% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-90.0%+63.7%+153.7 pp
1 year+127.6%-70.4%-198.0 pp
3-year CAGR—+19.1%—
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the income statement

Latest · FY2025
52.6M USD
Year-over-year change
+127.6%
4-year CAGR
-30.0%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How EBS compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +93.5% is the 4th highest of 11, against a peer median of -16.9%.
  • Net income amounts to 1.3% of revenue for EBS, versus a peer median of 21.6%.
EBS Competitors
Net Income for EBS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$364.23M USD+879.7%—121.5%
SIGASIGA Technologies, Inc.LTM Mar 2026$20.26M USD-58.2%-11.8%21.6%
ORGOOrganogenesis Holdings Inc.LTM Mar 2026-$284K USD+98.2%+33.6%0.1%
ESPREsperion Therapeutics, Inc.LTM Mar 2026-$7.42M USD+95.2%—1.8%
EBSEmergent BioSolutions Inc.LTM Mar 2026-$8.6M USD+93.5%—1.3%
SNDLSNDL Inc.LTM Mar 2026-CA$10.98M CAD+89.7%—1.2%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026-$44.17M USD-6.7%——
AQSTAquestive Therapeutics, Inc.LTM Mar 2026-$68.91M USD-27.1%—137.1%
PRTAProthena Corporation plcLTM Mar 2026-$151.18M USD-37.1%—260.9%
CMPSCOMPASS Pathways plcLTM Mar 2026-$178.95M USD-29.9%——
OLMAOlema Pharmaceuticals, Inc.LTM Mar 2026-$185.15M USD-43.6%——
Peer median (excluding EBS) —-16.9%+10.9%21.6%

Competitors are the stored peer set for EBS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.77B1.12B1.05B1.04B742.9M
Cost of Revenue980.4M644.5M689.3M668.2M392.3M
Gross Profit793.2M473M360M375.4M350.6M
Gross Margin44.7%42.3%34.3%36.0%47.2%
Research & Development235.2M188.3M111.4M70.7M53.8M
Selling, General & Admin348.7M339.5M356.7M298.7M186.6M
Operating Expenses451.8M643M1.09B484.1M240.4M
Depreciation & Amortization118.2M125M121.1M105.6M98.3M
EBITDA504.2M15.7M(47M)53.4M240.4M
EBITDA Margin28.4%1.4%-4.5%5.1%32.4%
Operating Income341.4M(170M)(726.4M)(108.7M)110.2M
Operating Margin19.2%-15.2%-69.2%-10.4%14.8%
Interest Income00000
Interest Expense34.5M37.3M87.9M71M59.3M
Other Income / Expenses(38.2M)(49M)(4.8M)(34.2M)(27.4M)
Income Before Tax303.2M(219M)(731.2M)(142.9M)82.8M
Pre-Tax Margin17.1%-19.6%-69.7%-13.7%11.1%
Income Tax Expense83.7M(7.4M)29.3M47.7M30.2M
Net Income219.5M(211.6M)(760.5M)(190.6M)52.6M
Net Margin12.4%-18.9%-72.5%-18.3%7.1%
EPS (Basic)4.10(4.22)(14.85)(3.60)0.98
EPS (Diluted)4.06(4.22)(14.85)(3.60)0.93
Weighted Avg Shares53.5M50.1M51.2M53M53.5M
Weighted Avg Shares (Diluted)54.1M50.1M51.2M53M56.7M

Emergent BioSolutions Inc.

NYSE:EBS

Intrinsic Alpha fair value

Locked

Current Price

$5.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.